SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)

1. Name of the Medicinal Product

Omniclar® 625 mg Tablets

(Amoxicillin 500 mg + Clavulanic acid 125 mg)

2. Qualitative and Quantitative Composition

Each film-coated tablet contains:

- Amoxicillin trihydrate equivalent to 500 mg Amoxicillin
- Potassium clavulanate equivalent to 125 mg Clavulanic acid

Excipients: Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, povidone, magnesium stearate, hypromellose, titanium dioxide, talc, polyethylene glycol.

3. Pharmaceutical Form

Film-coated tablet.

White to off-white, oval, biconvex tablet, debossed "OMC 625" on one side.

4. Clinical Particulars

4.1 Therapeutic Indications

Treatment of infections due to beta-lactamase producing organisms, including:

- Sinusitis, otitis media, tonsillitis, pharyngitis
- Acute exacerbations of chronic bronchitis, pneumonia
- Urinary tract infections (cystitis, pyelonephritis)
- Skin/soft tissue infections (cellulitis, abscesses, bites)
- Bone/joint infections (osteomyelitis)
- Dental infections (abscesses)

4.2 Posology and Method of Administration

- Adults & children ≥40 kg: 1 tablet every 12 hours. For severe infections, 1 tablet every 8 hours.
- Children < 40 kg: use paediatric suspensions.
- Renal impairment: dose adjustment required if CrCl <30 mL/min.
- Hepatic impairment: use with caution, monitor LFTs.
- Administration: oral, at the start of a meal.

4.3 Contraindications

- Hypersensitivity to penicillins or beta-lactams
- Previous cholestatic jaundice/hepatitis with co-amoxiclay
- Severe renal impairment (formulation dependent)

4.4 Warnings & Precautions

- Severe hypersensitivity reactions possible.
- Monitor LFTs in hepatic impairment.
- Risk of antibiotic-associated colitis.
- Crystalluria risk → maintain hydration.

4.5 Interactions

- Warfarin (increased INR)
- Allopurinol (rash risk)
- Probenecid (reduces renal clearance)
- Methotrexate (increased toxicity)
- Mycophenolate (reduced metabolite levels)

4.6 Pregnancy/Lactation

- Use if benefits outweigh risks.
- Passes into breast milk (possible diarrhoea/thrush in infants).

4.7 Effects on Ability to Driving/Use Machines

May cause dizziness, convulsions, or allergic reactions.

4.8 Undesirable Effects

- Very common: Diarrhoea
- Common: Nausea, vomiting, rash, thrush
- Uncommon: Headache, dizziness, indigestion
- Rare: Hepatitis, jaundice, severe skin reactions
- Very rare: Hematologic effects, interstitial nephritis

4.9 Overdose

- GI upset, crystalluria, renal impairment possible.
- Symptomatic treatment, hydration, hemodialysis removes drug.

5. Pharmacological Properties

5.1 Pharmacodynamics

Broad-spectrum penicillin + beta-lactamase inhibitor. ATC Code J01CR02.

5.2 Pharmacokinetics

- Absorbed rapidly, enhanced by food.
- Half-life ~1 hr.
- Excreted via urine.

5.3 Preclinical Safety

No evidence of mutagenicity or carcinogenicity.

6. Pharmaceutical Particulars

6.1 List of Excipients

Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, povidone, magnesium stearate, hypromellose, titanium dioxide, talc, polyethylene glycol.

6.2 Incompatibilities

Not applicable.

6.3 Shelf Life

24 months

6.4 Special Precautions for Storage

Store below 25°C. Protect from moisture. Keep out of reach of children.

6.5 Nature and Contents of Container

PVC/aluminium foil blister packs of 6, 10, 14, or 20 film-coated tablets.

6.6 Special Precautions for Disposal

No special requirements. Dispose in accordance with local regulations.

7. Marketing Authorisation Holder / Manufacture

A.C. Drugs Limited Plot C5/C6 Old Airport Road Emene, Enugu, Nigeria

8. Marketing Authorisation Number(s)

9. Date of First Authorisation / Renewal of the Authorisation

10. Date of Revision of the Text

September 2025

11. Legal Category

Prescription Only Medicine (Rx)